Concomitant with lifestyle therapy, patients with T2D with established or at high risk for ASCVD, CKD and/or HF should be prescribed antihyperglycemic agents proven to decrease the corresponding risks independent of their effects on glucose—namely, SGLT2 inhibitors and long-acting (LA) GLP1-RAs. This evidence concerns the gene SLC5A2 and atherosclerosis.